Orforglipron, a GLP-1 receptor agonist in tablet form, has proven effective in treating obesity in a phase 3 trial, offering a potential alternative to injectable treatments like Wegovy and Ozempic.
Obesity Canada’s 2025 clinical practice guideline update on pharmacotherapy for obesity management includes recommendations for obesity management in adults with specific co-morbidities.
A study of more than one million adolescents reveals a marked association between a low BMI in adolescence and an increased risk of osteoporosis in adulthood.
Obesity Canada experts provide 13 new and updated recommendations on the effectiveness, safety and appropriate use of pharmacotherapy in the management of obesity in adults.
A new report says the prevalence of obesity increased faster during the COVID-19 pandemic than it did over the course of more than a decade beforehand, specifically in young adults.
